☆ 4.6 Article

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Lancet Diabetes & Endocrinology (2020)

Get Full Text
Add to Collection

Journal

Lancet Diabetes & Endocrinology
Volume 8, Issue 5, Pages 377-391

Publisher

Elsevier BV
DOI: 10.1016/s2213-8587(20)30075-9

Keywords

-

Categories

Endocrinology & Metabolism

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.